research use only

Prazosin HCl Adrenergic Receptor antagonist

Name: Prazosin HCl
Brand: Selleck Chemicals
SKU: S1424
Availability: InStock
Rating: 5 (3 reviews)

Cat.No.S1424

Prazosin HCl (cp-12299-1) is a competitive alpha-1 adrenoceptor antagonist, used to treat high blood pressure or benign prostatic hyperplasia.

Chemical Structure

Molecular Weight: 419.86

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras GPR GluR Prostaglandin Receptor CXCR Adenosine Receptor P2 Receptor CCR Angiotensin Receptor Hedgehog/Smoothened S1P Receptor PKA Cannabinoid Receptor cAMP Glucagon Receptor SGLT Opioid Receptor Sigma Receptor PAR Endothelin Receptor LTR Neurokinin Receptor Guanylate Cyclase PKG LPA Receptor OX Receptor
Related Products	Zenidolol (ICI-118551) Hydrochloride Yohimbine HCl L755507 Atipamezole Higenamine hydrochloride Fenoterol hydrobromide Medetomidine HCl Rauwolscine hydrochloride Deoxycorticosterone acetate Detomidine HCl Naftopidil Demethyl-Coclaurine Scopine Buflomedil HCl Labetalone hydrochloride DL-Adrenaline Landiolol hydrochloride Noradrenaline bitartrate monohydrate Adrenergic α 1A Receptor/ADRA1A Antibody [C20D16] Alprenolol hydrochloride Fenoterol Clorprenaline HCl Moxisylyte hydrochloride L-765314 Fargesin Urapidil Isoprenaline Naftopidil DiHCl Tetryzoline Xylometazoline HCl

Chemical Information, Storage & Stability

Molecular Weight	419.86	Formula	C₁₉H₂₁N₅O₄·HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	19237-84-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	cp-12299-1			Smiles	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl

Solubility

In vitro
Batch:

DMSO : 3 mg/mL (7.14 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	alpha-adrenergic receptor ^[1]
In vitro	Prazosin leads to a significant increase in VEGF concentration in endothelial cells and angiogenesis only if eNOS is present. Prazosin binds to the α1-adrenergic receptors that are present on smooth muscle cells surrounding all larger blood vessels. ^[1] Prazosin (0.1 nM) blocks the increases in perfusion pressure caused by electrical stimulation of the perimesenteric nerves but does not significantly reduce the vasomotor effect of exogenous noradrenaline. ^[2]
In vivo	Prazosin application leads to the expansion of the capillary system by modulation of the hemodynamic environment (flow rate, shear stress) in skeletal muscle. Prazosin induces angiogenesis in extensor digitorum longus (EDL) muscles of C57BL/6 mice but not eNOS-knockout mice. ^[1] Prazosin (0.5-2.0 mg/kg) blocks Yohimbine-induced reinstatement of food and alcohol seeking, as well as footshock-induced reinstatement of alcohol seeking in rats. ^[3] Prazosin (0.2mg kg(-1) s.c.) causes an enhancement of a suppression of conditioned avoidance response in the presence of the dopamine D2 receptor antagonist raclopride (0.05-0.20 mg/kg s.c.) in rats. ^[4] Prazosin administration alone (1 mg/kg, s.c.) only slightly reduces horizontal activity during an initial 10 min measurement period, although it consistently reduces rearing in freely moving rats. Prazosin effectively suppresses the locomotor stimulation caused by either dose of MK-801 throughout the whole observation period in freely moving rats. ^[5]
References	[1] https://pubmed.ncbi.nlm.nih.gov/15231496/ [2] https://pubmed.ncbi.nlm.nih.gov/9262332/ [3] https://pubmed.ncbi.nlm.nih.gov/21318567/ [4] https://pubmed.ncbi.nlm.nih.gov/11129112/ [5] https://pubmed.ncbi.nlm.nih.gov/8864686/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05189977	Terminated	Post-traumatic Stress Disorder (PTSD)	Otsuka Pharmaceutical Development & Commercialization Inc.\|Iqvia Pty Ltd	September 7 2022	Phase 1
NCT04365257	Terminated	COVID-19	Johns Hopkins University\|Fast Grants	May 13 2020	Phase 2
NCT03045016	Completed	Acute Stress Disorder	Hospices Civils de Lyon	April 21 2017	Phase 2
NCT02193256	Completed	Cigarette Smoking\|Alcohol Use Disorders	Yale University\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	July 2014	Early Phase 1
NCT01178138	Completed	Continuous Methamphetamine Abuse	University of Arkansas\|National Institute on Drug Abuse (NIDA)	December 2009	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):